1.11
price down icon0.45%   -0.00
after-market Handel nachbörslich: 1.10 -0.01 -0.90%
loading
Schlusskurs vom Vortag:
$1.11
Offen:
$1.16
24-Stunden-Volumen:
16,383
Relative Volume:
0.15
Marktkapitalisierung:
$11.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-15.42M
KGV:
-0.6307
EPS:
-1.76
Netto-Cashflow:
$-13.41M
1W Leistung:
-8.68%
1M Leistung:
-26.81%
6M Leistung:
-52.16%
1J Leistung:
-46.36%
1-Tages-Spanne:
Value
$1.10
$1.20
1-Wochen-Bereich:
Value
$1.10
$1.20
52-Wochen-Spanne:
Value
$1.03
$3.10

Indaptus Therapeutics Inc Stock (INDP) Company Profile

Name
Firmenname
Indaptus Therapeutics Inc
Name
Telefon
801-701-7180
Name
Adresse
533 SOUTH 400 WEST, SALT LAKE CITY
Name
Mitarbeiter
7
Name
Twitter
Name
Nächster Verdiensttermin
2024-08-12
Name
Neueste SEC-Einreichungen
Name
INDP's Discussions on Twitter

Vergleichen Sie INDP mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
INDP 1.10 11.32M 0 -15.42M -13.41M -1.76
VRTX 467.12 119.83B 10.63B -479.80M -1.35B 13.33
REGN 762.38 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 567.35 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 232.27 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.83 24.08B 3.30B -501.07M 1.03B 11.54

Indaptus Therapeutics Inc Aktie (INDP) Neueste Nachrichten

pulisher
Nov 17, 2024

Maxim Group Has Lowered Expectations for Indaptus Therapeutics (NASDAQ:INDP) Stock Price - Defense World

Nov 17, 2024
pulisher
Nov 12, 2024

Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Nov 12, 2024
pulisher
Nov 12, 2024

Indaptus Therapeutics Inc (INDP) Quarterly 10-Q Report - Quartzy

Nov 12, 2024
pulisher
Nov 11, 2024

Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology - The Manila Times

Nov 11, 2024
pulisher
Nov 07, 2024

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Indaptus' Decoy20 Shows Promise: Phase 1 Trial Reports Safe Weekly Dosing in Cancer Study | INDP Stock News - StockTitan

Nov 07, 2024
pulisher
Oct 23, 2024

Indaptus Therapeutics to Present at Two Upcoming Investor Conferences - The Manila Times

Oct 23, 2024
pulisher
Oct 23, 2024

Indaptus Therapeutics partners with BeiGene for cancer study By Investing.com - Investing.com Canada

Oct 23, 2024
pulisher
Oct 22, 2024

Indaptus Therapeutics Shares Rise After Pact to Develop Cancer Treatment - Morningstar

Oct 22, 2024
pulisher
Oct 22, 2024

Indaptus Therapeutics partners with BeiGene for cancer study - Investing.com

Oct 22, 2024
pulisher
Oct 22, 2024

Indaptus Therapeutics Announces Clinical Supply Agreement - GlobeNewswire

Oct 22, 2024
pulisher
Oct 22, 2024

Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations - The Manila Times

Oct 22, 2024
pulisher
Oct 22, 2024

Indaptus Therapeutics, Inc. Enters into Clinical Supply Agreement with Beigene Switzerland GmbH - Marketscreener.com

Oct 22, 2024
pulisher
Oct 15, 2024

Provident Bank's First-Time Home Buyer Survey Reveals That While Homeownership Continues to Be Challenging, Many Americans Are Finding Their Home in Less Than a Year - The Manila Times

Oct 15, 2024
pulisher
Oct 15, 2024

Indaptus Therapeutics Initiates Unrestricted Enrollment of - GlobeNewswire

Oct 15, 2024
pulisher
Oct 13, 2024

Indaptus Therapeutics (INDP) Price Target Increased by 25.00% to 10.20 - MSN

Oct 13, 2024
pulisher
Oct 10, 2024

Indaptus Therapeutics Founder and Chief Scientific Officer - GlobeNewswire

Oct 10, 2024
pulisher
Oct 08, 2024

Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - The Manila Times

Oct 08, 2024
pulisher
Sep 26, 2024

Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Increases By 140.5% - Defense World

Sep 26, 2024
pulisher
Sep 26, 2024

Cybin (NYSEAMERICAN:CYBN) Shares Down 4.4% - Defense World

Sep 26, 2024
pulisher
Sep 26, 2024

Japan Tobacco Inc. (OTCMKTS:JAPAY) Short Interest Update - Defense World

Sep 26, 2024
pulisher
Sep 26, 2024

Sei Investments Co. Has $17.72 Million Position in Teradata Co. (NYSE:TDC) - Defense World

Sep 26, 2024
pulisher
Sep 24, 2024

Indaptus Therapeutics (NASDAQ:INDP) Stock Price Down 9.2% - Defense World

Sep 24, 2024
pulisher
Sep 19, 2024

Intelligent Bio Solutions Inc. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Operational Highlights - Marketscreener.com

Sep 19, 2024
pulisher
Sep 19, 2024

Kaskela Law LLC Announces Shareholder Investigation of Integra LifeSciences Holdings Corp. (NASDAQ: IART) and Encourages Long-Term IART Shareholders to Contact the Firm - Business Wire

Sep 19, 2024
pulisher
Sep 19, 2024

The Escalator: Imre, Kyverna Therapeutics, The Bloc and more - MM+M Online

Sep 19, 2024
pulisher
Sep 19, 2024

StockNews.com Downgrades Independent Bank (NASDAQ:INDB) to Sell - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Integrated BioPharma (OTCMKTS:INBP) Trading Down 2.2% - Defense World

Sep 19, 2024
pulisher
Sep 18, 2024

Indivior PLC REMINDER – INDV Stockholders Should Contact - GlobeNewswire

Sep 18, 2024
pulisher
Sep 18, 2024

IBTX stock hits 52-week high at $60.77 amid robust growth - Investing.com

Sep 18, 2024
pulisher
Sep 18, 2024

INDV Investors Have Opportunity to Lead Indivior PLC Securities Fraud Lawsuit - PR Newswire

Sep 18, 2024
pulisher
Sep 18, 2024

Northland Capmk Equities Analysts Cut Earnings Estimates for Indivior PLC (NASDAQ:INDV) - MarketBeat

Sep 18, 2024
pulisher
Sep 18, 2024

Holdings of Intelligent Bio Solutions Inc (INBS) are aligned with the stars - SETE News

Sep 18, 2024
pulisher
Sep 18, 2024

Upward Trajectory: Intelligent Bio Solutions Inc (INBS) Posts a Gaine, Closing at 2.48 - The Dwinnex

Sep 18, 2024
pulisher
Sep 18, 2024

Imunon (NASDAQ:IMNN) Shares Up 5.6% - Defense World

Sep 18, 2024
pulisher
Sep 17, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Indivior PLC of Class Action Lawsuit and Upcoming DeadlinesINDV - PR Newswire

Sep 17, 2024
pulisher
Sep 17, 2024

Financial Health Check: Examining Indivior Plc (INDV)’s Key Ratios - The Dwinnex

Sep 17, 2024
pulisher
Sep 17, 2024

Class Action Lawsuit Against Indivior PLC (NASDAQ:INDV) - TipRanks

Sep 17, 2024
pulisher
Sep 17, 2024

Ready to Jump After Recent Trade: Indivior Plc (INDV) - SETE News

Sep 17, 2024
pulisher
Sep 17, 2024

Indivior PLC Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsINDV - PR Newswire

Sep 17, 2024
pulisher
Sep 17, 2024

Intelligent Bio Solutions Inc’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle

Sep 17, 2024
pulisher
Sep 16, 2024

DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value - GlobeNewswire

Sep 16, 2024
pulisher
Sep 16, 2024

Technical analysis of Intelligent Bio Solutions Inc (INBS) stock chart patterns - US Post News

Sep 16, 2024
pulisher
Sep 16, 2024

Negative FDA AdCom vote on Ocaliva - The Pharma Letter

Sep 16, 2024
pulisher
Sep 16, 2024

The Gross Law Firm Reminds Indivior Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 1, 2024INDV - PR Newswire

Sep 16, 2024
pulisher
Sep 16, 2024

Piper Sandler Reaffirms “Overweight” Rating for Indivior (NASDAQ:INDV) - Defense World

Sep 16, 2024
pulisher
Sep 15, 2024

INDV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Indivior PLC Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire

Sep 15, 2024
pulisher
Sep 15, 2024

Indivior PLC (NASDAQ:INDV) Shares Sold by Royal London Asset Management Ltd. - MarketBeat

Sep 15, 2024
pulisher
Sep 13, 2024

INVESTOR ALERT: DiCello Levitt LLP Shareholder Class Action - GlobeNewswire

Sep 13, 2024
pulisher
Sep 13, 2024

Indivior's (INDV) Overweight Rating Reiterated at Piper Sandler - MarketBeat

Sep 13, 2024
pulisher
Sep 13, 2024

Intl Paper Co stock hits 52-week high at $49.25 amid market rally By Investing.com - Investing.com South Africa

Sep 13, 2024

Finanzdaten der Indaptus Therapeutics Inc-Aktie (INDP)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$19.00
price up icon 4.27%
$76.98
price up icon 1.23%
$39.53
price up icon 7.03%
$359.21
price down icon 0.88%
$187.76
price down icon 0.58%
$101.83
price up icon 2.00%
Kapitalisierung:     |  Volumen (24h):